In Q4 2025, RTW Investments held 86 positions worth $9.5B. They initiated 23 new positions and exited 56. Their largest holding was MDGL ($1.2B). Portfolio value grew +22.9% versus the prior quarter.
Frequently asked questions
What stocks did RTW Investments own in Q4 2025?
RTW Investments held 86 biotech stocks in their 13F portfolio in Q4 2025. Their top positions include MDGL, INSM, PTCT, ARGX, PTGX. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was RTW Investments's portfolio worth in Q4 2025?
RTW Investments's tracked biotech portfolio was worth $9.5B across 86 positions, with total assets under management of approximately $10B. Portfolio values are based on 13F filings with the SEC.
What did RTW Investments buy in Q4 2025?
RTW Investments initiated 23 new positions in Q4 2025, including APLS, RGEN, PODD, CELC, KOD and 18 more. They also increased 24 existing positions.
What did RTW Investments sell in Q4 2025?
RTW Investments fully exited 56 positions in Q4 2025, including BIOA, GKOS, GMED, ARTV, TXG and 51 more. They also trimmed 12 existing positions.
Is RTW Investments a biotech fund?
Data-driven biotech fund led by a physician-investor who combines clinical expertise with quantitative analysis. RTW takes concentrated positions across the biotech lifecycle, from crossover privates to public equities, with a focus on therapeutic areas where clinical data can be independently modeled.
Want AI analysis, insider signals, and catalyst overlays for RTW Investments?
View latest RTW Investmentsportfolio →